Early weight loss ≥ 2% or ≥ 3% by 4 weeks in structured weight-loss programs is significantly associated with achieving ≥ 5% or ≥ 10% total weight loss, respectively, by 16 weeks in adults with class ...

Get the skinny on getting skinny. — -- Just in time for swimsuit season, a new study has come out saying there's very little scientific evidence to prove most diet and weight-loss regimens ...

This year’s Super Bowl commercials relied on comic relief and highlighted noncontroversial topics, like streaming and entertainment. But a couple of commercials in the lineup still managed to stir ...

With all the to-do about the inauguration and the Super Bowl, you may not have noticed an alarming trend in TV's obsession with making us all skinnier. I mean, we're used to a bountiful Queen Latifah ...

The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients’ plan members trying a lifestyle-first approach, as well as additional clinical ...

Are you looking for a quick way to lose those unwanted pounds? The advertisements that promise quick weight loss are everywhere on television and in magazines. Millions of people in America will go on ...

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move more”—rarely works because everyone’s body is different. That’s where personalized ...

CVS Health shared data from its CVS Weight Management program in which participants achieved more than 15% weight loss on average, including existing anti-obesity medication users who succeeded in ...

If you’ve ever Googled “best weight loss program,” you know the options are endless—and overwhelming. From meal delivery to macro tracking, it can be hard to know which approach actually works, and ...

MALAGA, Spain—Patients with obesity treated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) can achieve weight loss in the real world similar to what has ...

Utilization of GLP-1s, short for glucagon-like peptide 1 agonists, has been building as the drugs, originally approved for diabetes, are used more frequently for weight loss. Insurers have been ...